PharmaCorp Achieves Exceptional Growth with a 75 Percent Revenue Surge in 2025
New York, Thursday, 30 April 2026.
PharmaCorp’s latest earnings report reveals a staggering 75 percent increase in late 2025 revenue. This impressive financial surge highlights the company’s successful expansion strategies and strong market demand.
Breaking Down the Fourth Quarter Surge
On April 29, 2026, the Saskatoon-based pharmacy acquisition platform, PharmaCorp RX Inc., which trades on the TSX Venture Exchange under the ticker symbol PCRX, released its highly anticipated financial results for the quarter ending December 31, 2025 [1][5]. The company generated $7.7 million in fourth-quarter revenue, representing a 75 percent increase from the $4.4 million reported in the same period of 2024 [1]. Gross profit experienced an even steeper trajectory, rising by 78 percent to reach $2.9 million, compared to $1.7 million in the fourth quarter of the prior year [1][3][4]. This profitability was bolstered by a slight margin expansion, moving from 38 percent in late 2024 to 39 percent in the final quarter of 2025 [1].
Fiscal Year 2025 and Strategic Acquisitions
The annual figures for 2025 paint a picture of aggressive scaling. For the full fiscal year, PharmaCorp achieved $20.9 million in revenue, a massive leap from the $5.8 million recorded in 2024 [1]. This top-line expansion was accompanied by a robust increase in annual gross profit, which climbed to $8.3 million from $2.2 million the previous year [1]. Furthermore, the company’s Adjusted EBITDA surged to $3.5 million for 2025, significantly outpacing the $0.85 million generated in 2024 [1]. However, the rapid expansion did result in a widened annual net loss of $1.4 million for 2025, compared to $1.1 million in 2024 [1].
Capital Fortification and Executive Moves
To sustain its rapid growth trajectory, PharmaCorp significantly fortified its balance sheet in late 2025. On November 12, 2025, the corporation closed a bought deal public offering, securing gross proceeds of approximately $23 million [1]. This capital injection dramatically improved the company’s liquidity, leaving PharmaCorp with $25.9 million in cash reserves as of December 31, 2025, representing an increase of 100.775 percent from the $12.9 million held at the end of 2024 [1].